Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

Recruiting now · Phase 2

Conditions studied: Biliary Tract Carcinoma

In brief

This is a randomized, open-label, phase II study evaluating first-line treatment for advanced gallbladder cancer. It aims to assess the efficacy, safety, pharmacokinetics, and immunogenicity of the ZG005 in Combination with gemcitabine and cisplatin as first-line therapy in Participants with advanced gallbladder cancer.

Key facts

Study ID

NCT07099547

Run by

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

People needed

60

Starts

2025-12-02

Expected to finish

2027-12-01

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fully understand the study and voluntarily sign the informed consent form.
• Subjects with a histopathological or cytologically diagnosis of Gallbladder cancer.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Life expectancy of at least 3 months.

You may not qualify if…

• Participants were deemed unsuitable for participating in the study by the investigator for any reasons.

Where it is running

• The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.